Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Bevacizumab Plus EGFR Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB-IV EGFR-mutant Non-small Cell Lung Cancer: a Prospective,Multicenter, Non-interventional,Real-world Study

NCT04575415 is registered in ClinicalTrials.gov with Guangdong Association of Clinical Trials as lead sponsor.

NCT NCT04575415
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04575415 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Bevacizumab Plus EGFR Tyrosine Kinase Inhibitors in Chinese Patients With Stage IIIB-IV EGFR-mutant Non-small Cell Lung Cancer: a Prospective,Multicenter, Non-interventional,Real-world Study
Lead sponsor
Guangdong Association of Clinical Trials
Phase
Observational
Overall status
Unknown status
Start date
October 7, 2020
Completion date
December 31, 2023
Enrollment
272 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc